



GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer

October 14, 2025

Renowned physician–scientist and healthcare innovator to lead GeneDx’s vision for a new era of lifelong health informed by genomics

GAITHERSBURG, Md.–(BUSINESS WIRE)--Oct. 14, 2025-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer. Dr. Lee will spearhead GeneDx’s vision to unlock the power of genomics to help every person live their healthiest life.

As Chief Precision Medicine Officer, Dr. Lee will lead GeneDx’s work to empower customizable precision medicine as the standard of care, leveraging the power of genomics to predict, prevent, and optimize health outcomes throughout a person’s lifetime. Precision medicine can also generate regulatory grade evidence to connect genomics to real-world outcomes – accelerating new discoveries and helping ensure every therapy is developed with purpose, precision, and patient impact. She will work closely with policymakers, health systems, biopharmaceutical companies, advocacy groups, payers, and global thought leaders to accelerate the adoption of precision medicine throughout healthcare. Dr. Lee will also help define, expand, and strengthen GeneDx’s external ecosystem, forging partnerships that deliver positive impact for patients and enable innovation. She will supercharge the company’s work across the industry to make the shift from today’s reactive model of diagnosing rare diseases after symptoms arise to a world where genomes are sequenced at birth or as early as possible, empowering healthier lives from the very start.

“Dr. Lee is a visionary who brings together clinical care, scientific rigor, policy experience, and a deep sense of humanity,” said Katherine Stueland, President and Chief Executive Officer, GeneDx. “Her leadership will help shape the next frontier for GeneDx as we champion the future of precision medicine and drive a future where genomic insights guide healthier futures at the earliest moment possible, empowering families and informing proactive care across healthcare.”

“GeneDx has already transformed how families discover the ‘why’ behind devastating rare disease diagnoses,” said Dr. Lee. “The next step is to activate those genomic insights to power prediction, prevention, and timely precision medical interventions. I’m honored to join a company that not only leads in genomic data and diagnostics but also has the courage and forward-looking perspectives to reimagine what precision medicine can be for generations to come.”

Dr. Lee joins GeneDx from the Advanced Research Projects Agency for Health (ARPA-H), where she designed and directed high-impact public-private programs to accelerate individualized genetic medicines, including the recently launched THRIVE, Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines. A physician–scientist, neurosurgeon, and board-certified anesthesiologist, she brings more than two decades of leadership across academia, biotechnology, and global industry, including senior executive roles at Samsung Bioepis, Novartis Institutes of Biomedical Research, and BioMarin.

Dr. Lee earned her MD-PhD in Neuroscience from the Albert Einstein College of Medicine as part of the NIH Medical Scientist Training Program. She holds an AB in Chemistry and East Asian Languages and Civilizations from Harvard University, completed her residency training at Washington University School of Medicine in St. Louis and UCSF, and holds additional certifications in Bioethics (Columbia University) and Psychedelic-Assisted Therapy (California Institute of Integral Studies).

About GeneDx

GeneDx (Nasdaq: WGS) is the global leader in rare disease diagnosis, transforming the way medicine is practiced by making genomics the starting point for health, not the last resort. We bring together unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the largest rare disease dataset – built over 25 years from millions of genomic tests and deep clinical insights. This unparalleled foundation powers our ExomeDx™ and GenomeDx™ tests, giving clinicians the highest likelihood of delivering a timely, accurate diagnosis. GeneDx is shaping the future of healthcare by moving the standard of care from sick care to proactive healthcare. While our roots are in rare disease diagnosis, our commitment extends beyond – growing with the families we serve – as a trusted partner at every stage of life. For more information, visit [genedx.com](https://www.genedx.com) and connect with us on [LinkedIn](#), [Facebook](#), and [Instagram](#).

Forward Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement plans to accelerate and unlock the full potential of precision medicine, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic

direction. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251014928013/en/): <https://www.businesswire.com/news/home/20251014928013/en/>

Investor Relations Contact:

Investors@GeneDx.com

Media Contact:

Press@GeneDx.com

Source: GeneDx